Development of quantitative structure-pharmacokinetic relationships.

Quantitative structure-activity relationships (QSAR) relating biological activity to physiochemical descriptors have been successfully used for a number of years. It is also long recognized that pharmacokinetic parameters may play an important and even determinant role in drug action. This prompted several researchers to focus attention to pharmacokinetic parameters as potential descriptors in quantitative drug design. A number of examples of quantitative structure-pharmacokinetic relationships (QSPR) have appeared in the literature. The present contribution reviews some developments in this field. In particular, a number of concepts and problems are critically discussed, rather than compilations of examples already published in recent reviews. Attention will be paid to the main processes of the pharmacokinetic or toxicokinetic phase in drug action, including absorption, distribution and elimination (biotransformation and excretion). It is clear that quantitative approaches are of considerable interest to toxicologists, since these methods may contribute to the development of real predictive toxicology.

[1]  I. Kapetanovic,et al.  Metabolic structure-activity relationship for a homologous series of phenacetin analogs. , 1979, The Journal of pharmacology and experimental therapeutics.

[2]  E. R. Cooper,et al.  Kinetic analysis of relationship between partition coefficient and biological response. , 1981, Journal of pharmaceutical sciences.

[3]  B Testa,et al.  Quantitative structure-activity relationships in drug metabolism and disposition: pharmacokinetics of N-substituted amphetamines in humans. , 1980, Journal of pharmaceutical sciences.

[4]  Yoshimasa Takahashi,et al.  Computer-assisted structure—carcinogenicity studies on polycyclic aromatic hydrocarbons by pattern recognition methods , 1981 .

[5]  Paul J. Lewi,et al.  Chapter 5 – Computer Technology in Drug Design , 1976 .

[6]  Gerhard Levy,et al.  Development of In Vitro Dissolution Tests which Correlate Quantitatively with Dissolution Rate-Limited Drug Absorption in Man , 1965 .

[7]  Klaus-Jürgen Schaper.  Absorption of Ionizable Drugs: Nonlinear Dependence on log P, pKa and pH ‐ Quantitative Relationships , 1982 .

[8]  A. Leo,et al.  Substituent constants for correlation analysis in chemistry and biology , 1979 .

[9]  J. Hadgraft.  Percutaneous absorption: possibilities and problems , 1983 .

[10]  S. Yalkowsky,et al.  A Physical Chemical Basis for the Design of Orally Active Prodrugs , 1980 .

[11]  J. Holtzman,et al.  Role of substrate lipophilicity on the N-demethylation and type I binding of 3-O-alkylmorphine analogues. , 1983, Journal of medicinal chemistry.

[12]  Yoshimura Yoshinobu,et al.  Structure-gastrointestinal absorption relationship of penicillins☆ , 1983 .

[13]  Rf Rekker,et al.  THE HYDROPHOBIC FRAGMENTAL CONSTANT; AN EXTENSION TO A 1000 DATA POINT SET , 1979 .

[14]  G. Tucker,et al.  Measurement of the renal clearance of drugs. , 1981, British journal of clinical pharmacology.

[15]  W. Ritschel,et al.  Prediction of the volume of distribution from in vitro data and use for estimating the absolute extent of absorption. , 1980, International journal of clinical pharmacology, therapy, and toxicology.

[16]  C. George.  Drug Metabolism by the Gastrointestinal Mucosa , 1981, Clinical pharmacokinetics.

[17]  C. Hansch.  Recent Advances in Biochemical QSAR , 1978 .

[18]  B. Testa,et al.  The lipophilicity of deuterium atoms. A comparison of shake-flask and HPLC methods , 1984 .

[19]  E. Tomlinson.  Chromatographic hydrophobic parameters in correlation analysis of structure-activity relationships. , 1975, Journal of chromatography.

[20]  F. J. D. Carlo.  Metabolism, Pharmacokinetics, and Toxicokinetics Defined , 1982 .

[21]  S Oie,et al.  Effect of altered plasma protein binding on apparent volume of distribution. , 1979, Journal of pharmaceutical sciences.

[22]  M. Rowland,et al.  Influence of route of administration on drug availability. , 1972, Journal of pharmaceutical sciences.

[23]  R Franke.  On the interpretability of quantitative structure-activity relationships (QSAR). , 1979, Il Farmaco; edizione scientifica.

[24]  F. D. Di Carlo.  Metabolism, pharmacokinetics, and toxicokinetics defined. , 1982, Drug metabolism reviews.

[25]  E. J. Ariëns.  Modulation of Pharmacokinetics by Molecular Manipulation , 1971 .

[26]  T. Schultz,et al.  Structure-toxicity relationships of selected nitrogenous heterocyclic compounds II. Dinitrogen molecules , 1982, Archives of environmental contamination and toxicology.

[27]  C. Hansch.  Quantitative Relationships Between Lipophilic Character and Drug Metabolism , 1972 .

[28]  P. McNamara,et al.  Effect of plasma protein and tissue binding on the biologic half‐life of drugs , 1978, Clinical pharmacology and therapy.

[29]  J. Beisler,et al.  Toxicity quantitative structure--activity relationships of colchicines. , 1981, Journal of medicinal chemistry.

[30]  S. Unger.  Consequences of the Hansch Paradigm for the Pharmaceutical Industry , 1980 .

[31]  J. Bridges,et al.  The relationship between chemical structure and the in vivo metabolism of an homologous series of n‐alkyl carbamates , 1982, The Journal of pharmacy and pharmacology.

[32]  G. Suchowsky,et al.  BIOLOGICAL ACTIVITY AND CHEMICAL STRUCTURE. , 1963, Nihon Naibunpi Gakkai zasshi.

[33]  H Kubinyi,et al.  Lipophilicity and drug activity. , 1979, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[34]  C. Hansch,et al.  Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice. , 1978, Journal of medicinal chemistry.

[35]  A J Aguiar,et al.  Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate. , 1967, Journal of pharmaceutical sciences.

[36]  L. Dittert,et al.  Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates. , 1969, Journal of pharmaceutical sciences.

[37]  A. J. Stuper,et al.  Computer assisted studies of chemical structure and biological function , 1979 .

[38]  N. Peppas.  Book reviewDermal and transdermal absorption: R. Brandau and B.H. Lippold, APV Paperback Series, Vol. 4, Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1982, 254 pages, DM 70.50 , 1986 .

[39]  D Cutler,et al.  Assessment of rate and extent of drug absorption. , 1981, Pharmacology & therapeutics.

[40]  John G. Wagner,et al.  Fundamentals of Clinical Pharmacokinetics , 1975 .

[41]  E. Kutter,et al.  11 - Absorption, Distribution, and Metabolism of Drugs , 1983 .

[42]  E. Tomlinson,et al.  Correlations between alkane/water and octan-1-ol/ water distribution coefficients and isocratic reversed-phase liquid chromatographic capacity factors of acids, bases and neutrals , 1983 .

[43]  J. Dearden,et al.  Computer modelling studies of time-variant biological response† , 1979 .

[44]  L. Dittert,et al.  Drug absorption. 3. Effect of membrane storage on the kinetics of drug absorption. , 1970, Journal of pharmaceutical sciences.

[45]  B. Testa,et al.  Concepts in drug metabolism , 1980 .

[46]  C. Hansch,et al.  Selection of a reference partitioning system for drug design work. , 1975, Journal of pharmaceutical sciences.

[47]  J. Vallner.  Binding of drugs by albumin and plasma protein. , 1977, Journal of pharmaceutical sciences.

[48]  D. Breimer.  Towards better safety of drugs and pharmaceutical products : proceedings of the 39th International Congress of Pharmaceutical Sciences of F.I.P., held in Brighton, U.K., September 3-7, 1979 , 1980 .

[49]  J. Dearden.  Quantitative approaches to drug design : proceedings of the Fourth European Symposium on Chemical Structure-Biological Activity: Quantitative Approaches, Bath, U.K., September 6-9, 1982 , 1983 .

[50]  D. Winne.  Influence of blood flow on intestinal absorption of xenobiotics. , 1980, Pharmacology.

[51]  J. Topliss.  Quantitative structure-activity relationships of drugs , 1983 .

[52]  E. Lien.  Structure—Absorption—Distribution Relationships: Significance for Drug Design , 1975 .

[53]  C. Hansch,et al.  p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure , 1964 .

[54]  R. Notari.  Prodrug design. , 1981, Pharmacology & therapeutics.

[55]  A. Hopfinger.  Computer-assisted drug design. , 1985, Journal of medicinal chemistry.

[56]  J. Watanabe,et al.  Relationship between partition coefficients and apparent volumes of distribution for basic drugs. I. , 1978, Chemical & pharmaceutical bulletin.

[57]  Strategy of Drug Design: A Molecular Guide to Biological Activity , 1975 .

[58]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[59]  R D Cramer,et al.  Application of quantitative structure-activity relationships in the development of the antiallergic pyranenamines. , 1979, Journal of medicinal chemistry.

[60]  E. J. Ariëns.  Design of Safer Chemicals , 1980 .

[61]  Yoshimasa Takahashi,et al.  Computer-assisted structure—carcinogenicity studies on polynuclear aromatic hydrocarbons by pattern recognition methods: The role of the bay and l-regions , 1982 .

[62]  W M Rand,et al.  Nitrosamine carcinogenicity: a quantitative Hansch-Taft structure-activity relationship. , 1978, Chemico-biological interactions.

[63]  Barry L. Levinson,et al.  Quantitative Drug Design: A Critical Introduction , 1979, The Yale Journal of Biology and Medicine.

[64]  R K Jain,et al.  Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.

[65]  P. Brown,et al.  Quantitative structure-retention relationships for purine compounds on reversed-phase packings , 1983 .

[66]  P. N. Craig,et al.  Carcinogenesis: a predictive structure-activity model. , 1982, Journal of toxicology and environmental health.

[67]  B. Testa,et al.  ENZYMATIC HYDROLYSIS BY MOUSE SKIN HOMOGENATES: STRUCTURE-METABOLISM RELATIONSHIPS OF PARA-NITROBENZOATE ESTERS , 1981 .

[68]  Corwin Hansch,et al.  The physicochemical approach to drug design and discovery (QSAR) , 1981 .

[69]  K. Buisman.  Strategy in Drug Research , 1982 .

[70]  W J Jusko,et al.  Plasma and tissue protein binding of drugs in pharmacokinetics. , 1976, Drug metabolism reviews.

[71]  J. M. Rossum.  Significance of Pharmacokinetics for Drug Design and the Planning of Dosage Regimens , 1971 .

[72]  S. Toon,et al.  Structure-pharmacokinetic relationships among the barbiturates in the rat. , 1983, The Journal of pharmacology and experimental therapeutics.

[73]  G. Sudlow,et al.  Further characterization of specific drug binding sites on human serum albumin. , 1976, Molecular pharmacology.

[74]  A. Leo,et al.  Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents. , 1982, Journal of medicinal chemistry.

[75]  A. Garzia,et al.  Quantitative structure-selectivity relationships: selective drug design. , 1979, Journal of pharmaceutical sciences.

[76]  R. M. Hyde,et al.  Physiochemical-activity relations in practice. 1. A rational and self-consistent data bank. , 1975, Journal of medicinal chemistry.

[77]  G. Amidon,et al.  Intestinal absorption of amino acid derivatives: structural requirements for membrane hydrolysis. , 1983, Journal of pharmaceutical sciences.

[78]  K J Schaper,et al.  Quantitative structure-pharmacokinetic relationships and drug design. , 1981, Pharmacology & therapeutics.

[79]  M. Horning,et al.  Drug metabolism and distribution , 1983 .

[80]  Roelof F. Rekker,et al.  The hydrophobic fragmental constant, its derivation and application: A means of characterizing membrane systems , 1977 .

[81]  Ritschel Wa,et al.  Prediction of the volume of distribution from in vitro data and use for estimating the absolute extent of absorption. , 1980 .

[82]  Toshio Fujita,et al.  The Correlation of Biological Activity of Plant Growth Regulators and Chloromycetin Derivatives with Hammett Constants and Partition Coefficients , 1963 .

[83]  B. Testa,et al.  The development of a hydration factor ω and its relation to correction terms in current hydrophobic fragmental systems , 1983 .

[84]  Bernard Testa,et al.  Drug Metabolism: Chemical and Biochemical Aspects , 1976 .

[85]  S. Toon,et al.  QUANTITATIVE STRUCTURE PHARMACOKINETIC ACTIVITY RELATIONSHIPS WITH SOME TETRACYCLINES , 1979, The Journal of pharmacy and pharmacology.

[86]  W. Nimmo.  Drugs, Diseases and Altered Gastric Emptying , 1976, Clinical pharmacokinetics.

[87]  J. Watanabe,et al.  Relationship between partition coefficients and apparent volumes of distribution for basic drugs. II. , 1978, Chemical & pharmaceutical bulletin.